TYROBP
TYROBP, also known as DAP12 or KARAP, is a transmembrane adaptor protein that couples activating immune receptors to intracellular tyrosine kinase signalling. It carries an ITAM in its cytoplasmic domain and drives activation in myeloid and natural killer cells. Browse Assay Genie's current range of TYROBP research reagents below, or read on for the biology behind the target.
TYROBP is an adapter protein that associates non-covalently with activating receptors on the surface of many immune cells. After the receptors bind ligand, the ITAM of TYROBP is tyrosine-phosphorylated. This leads to activation of further tyrosine kinases and then to cell activation. The NCBI summary notes that it may bind ZAP-70 and SYK. In some cells TYROBP also has an inhibitory role.
The partner receptors are diverse. TYROBP works with members of the CD300 and CD200R families, and with CLEC5A/MDL1, SIRPB1 and TREM1. In natural killer cells it associates with KIR2DS2 and the KLRD1/KLRC2 heterodimer. It also enhances trafficking, surface expression and stability of KIR2DS1, KIR2DS2 and KIR2DS4. It is required for integrin-mediated neutrophil activation. With TREM2 it supports dendritic cell maturation and survival, up-regulation of CCR7, and formation of multinucleated giant cells. It also stabilises the TREM2 C-terminal fragment, which suppresses release of pro-inflammatory cytokines.
In microglia, TYROBP is required with TREM2 for phagocytosis of apoptotic neurons. It is required with ITGAM/CD11B for microglial superoxide production during brain development, and it promotes pro-inflammatory responses after nerve injury. It is also needed for CSF1-mediated osteoclast cytoskeletal organisation and multinucleation. In liver dendritic cells it positively regulates IRAK3 expression and IL10 production, and it negatively regulates B cell proliferation. Mutations in the TYROBP gene are associated with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL, Nasu-Hakola disease), as are mutations in TREM2. The gene has multiple transcript variants encoding distinct isoforms.
TYROBP acts with TREM2 in microglial phagocytosis of apoptotic neurons and in responses to nerve injury.
TYROBP links KIR and KLRD1/KLRC2 receptors to NK cell activation and supports their surface expression and stability.
TYROBP mediates activation of neutrophils, monocytes and dendritic cells through TREM1, SIRPB1, CLEC5A and CD300 family receptors.
TYROBP is required for osteoclast organisation, and its mutation is linked to Nasu-Hakola disease, which affects bone and brain.
TYROBP is an adapter protein that associates with activating receptors on immune cells. When the receptors bind ligand, its ITAM is tyrosine-phosphorylated, which triggers further tyrosine kinase activation and cell activation. It can also have an inhibitory role in some cells.
TYROBP is also called DAP12, KARAP, PLO-SL and PLOSL. Its earlier names include TYRO protein tyrosine kinase binding protein and polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy. The gene produces multiple transcript variants that encode distinct isoforms.
Mutations in TYROBP are associated with PLOSL, also called Nasu-Hakola disease, as are mutations in its putative receptor TREM2. Mouse and rat both have a Tyrobp ortholog; check the datasheet of any product for its validated reactivity.
Receptor partners, downstream kinases and cytokine pathway targets linked to TYROBP signalling in myeloid and NK cells.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O43914; product specifications from Assay Genie datasheets.